Clinical Research, Pharma & Healthcare FinancingMerck, Eisai Update Phase 3 LEAP-015 Trial for GE AdenocarcinomaBusiness WireJanuary 27, 2025February 21, 2025 by Business WireJanuary 27, 2025February 21, 2025059 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-015 trial evaluating...
